Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significantly greater reductions in BMI, waist circumference, and body weight compared to GLP-1 receptor agonists (semaglutide, dulaglutide), insulin, and placebo in patients with obesity or type 2 diabetes.
Tirzepatide is a once-weekly injectable medication that activates two gut hormones (GIP and GLP-1) to significantly reduce body weight and waist circumference. Clinical data shows it is more effective than existing GLP-1 drugs (like semaglutide), insulin, and placebo. It is prescribed for adults with obesity or type 2 diabetes, often starting at a low dose (2.5 mg) and increasing to 5, 10, or 15 mg to minimize side effects. Common side effects include nausea and diarrhea, which are usually mild and temporary. It should be used alongside diet and exercise.
Meta analysis results showed that compared with the glucagon like peptide-1 receptor agonist (GLP-1 RAs), placebo and insulin groups, tirzepatide could significantly reduce the BMI... In terms of decreasing waist circumference, tirzepatide has a more significant advantage... In the analysis of body weight, tirzepatide showed a more significant reduction effect compared to the control group
Why this rating
Based on a systematic review and meta-analysis of 12 randomized controlled trials involving 11,758 patients.
Source
Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials
Wenting Cai et al. · Frontiers in Public Health · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →